Pratteln, Switzerland, July 20, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces its inclusion in the SXI Life Sciences® (SIX/Bloomberg: SLIFEX) and SXI Bio+Medtech® (SIX/Bloomberg: SBIOMX) indices of the SIX Swiss Exchange.
Following the SIX Swiss Exchange’s ordinary index review, Santhera has been informed that it meets the criteria for inclusion in two healthcare indices: SXI Life Sciences®, which includes pharmaceutical, biotechnology and medical technology companies, and its more narrowly defined sub-index SXI Bio+Medtech®, focused on biotech and medtech companies. Santhera’s inclusion in both indices will be effective on September 21, 2020.
“We are pleased to be included in these important life science industry indices, which will contribute to raising Santhera’s profile and heighten its visibility in the international investor community,” commented Andrew Smith, Chief Financial Officer of Santhera.
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera is building a Duchenne muscular dystrophy (DMD) product portfolio to treat patients irrespective of causative mutations, disease stage or age. A marketing authorization application for Puldysa® (idebenone) is currently under review by the European Medicines Agency. Santhera has an option to license vamorolone, a first-in-class anti-inflammatory drug candidate with novel mode of action, currently investigated in a pivotal study in patients with DMD to replace standard corticosteroids. The clinical stage pipeline also includes lonodelestat (POL6014) to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases, as well as omigapil and an exploratory gene therapy approach targeting congenital muscular dystrophies. Santhera out-licensed ex-North American rights to its first approved product, Raxone® (idebenone), for the treatment of Leber's hereditary optic neuropathy (LHON) to Chiesi Group. For further information, please visit www.santhera.com.
Raxone® and Puldysa® are trademarks of Santhera Pharmaceuticals.
For further information please contact:
Eva Kalias, Head External Communications
Phone: +41 79 875 27 80
Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
# # #